| Her works are taking place among elite |
|
|
|
New improved processes, doubling the capacity of Pfizer's biotechnology facility in Strangeness. Now the factory is rewarded with a prestigious award. International Society for Pharmaceutical Engineering has selected Pfizer in Strangeness who works in this year's competition with 26 other facilities worldwide in the category of "operational excellence".
The factory manufactures Pfizer, the active ingredient to two biologics,
and growth hormone Genotropin, and SOMAVERT, an anti-abnormal giant,
acromegaly.
We received the award for the new facility which we opened in August 2009, says plant manager Kirsti Gjellan.
But what exactly is it you done that you rewarded for?
It is so much fun. Pfizer has been working with a new innovative process
to Genotropin, and it has led to a completely new technology. With it,
we on the same platform, different products, it is more flexible than
before and we increase production capacity so that it almost doubled.
If you increase capacity so much, you can produce more products in the factory?
Yes, and with it we can bring in additional production. First, we look internally within Pfizer, and we can also become a contract manufacturer for companies outside the group.
Before Pfizer decided to build in Strangeness was fierce competition
between different possible locations around the world. What is most
important for you to be competitive?
First and foremost, that we should maintain and develop the expertise
that exists here. We have a strong history of Strangeness were very
early stage biotech manufacturing. We started making Genotropin in the
mid-1980s.
|
|
| Last Updated ( Monday, 09 May 2011 ) |
| < Prev | Next > |
|---|
